Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party

Livio Pagano, Giovanna Rosaria Mansueto, Antonella Venditti, Ferdinando Ferrara, G D'Arena, Cg Valentini, G Pietrantuono, R Guariglia, Mc Martorelli, O Villani, D Onofrillo, A Falcone, G Specchia, G Semenzato, N Di Renzo, L Mastrullo, A Palumbo, P. Musto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

62 Citazioni (Scopus)

Abstract

The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.
Lingua originaleEnglish
pagine (da-a)1499-1502
Numero di pagine4
RivistaAnnals of Oncology
Volume23
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • plasmacell leukemia

Fingerprint

Entra nei temi di ricerca di 'Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party'. Insieme formano una fingerprint unica.

Cita questo